Review for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

Mapping Intimacies ◽

10.1111/dom.13979/v2/review1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Decision letter for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v2/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Diabetes Obesity and Metabolism ◽

10.1111/dom.13979 ◽

2020 ◽

Vol 22 (6) ◽

pp. 938-946 ◽

Author(s):

Juan Pablo Frias ◽

Michael A. Nauck ◽

Joanna Van ◽

Charles Benson ◽

Ross Bray ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Insulinotropic Peptide

Download Full-text

Review for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v1/review2 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Decision letter for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v1/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Author response for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v2/response1 ◽

2020 ◽

Author(s):

Juan Pablo Frias ◽

Michael A Nauck ◽

Joanna Van ◽

Charles Benson ◽

Ross Bray ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Author Response ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Review for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v1/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study

Journal of Diabetes Investigation ◽

10.1111/jdi.12749 ◽

2017 ◽

Vol 9 (3) ◽

pp. 558-566 ◽

Author(s):

Antonio Nino ◽

Inaha Okuda ◽

Timothy H Wilson ◽

Lynn Yue ◽

Hiromu Nakajima ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Japanese Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

Endocrine Journal ◽

10.1507/endocrj.ej14-0147 ◽

2014 ◽

Vol 61 (10) ◽

pp. 949-959 ◽

Author(s):

Yasuo Terauchi ◽

Yoichi Satoi ◽

Masakazu Takeuchi ◽

Takeshi Imaoka

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Receptor Agonist ◽

Japanese Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2012.01590.x ◽

2012 ◽

Vol 14 (6) ◽

pp. 565-574 ◽

Author(s):

T. Haak ◽

T. Meinicke ◽

R. Jones ◽

S. Weber ◽

M. von Eynatten ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Initial Combination

Download Full-text

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

Diabetic Medicine ◽

10.1111/j.1464-5491.2012.03745.x ◽

2012 ◽

Vol 29 (10) ◽

pp. 1260-1267 ◽

Author(s):

G. Grunberger ◽

A. Chang ◽

G. Garcia Soria ◽

F. T. Botros ◽

R. Bsharat ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text